Topics and Pearls
- Disease states such as acne, alopecia, atopic dermatitis, psoriasis, psoriatic arthritis, seborrheic dermatitis, skin cancer, and vitiligo
- Conference insights
- Emerging data and pharmaceutical developments
Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Interview Intersection: Expert Interviews From February 2025
Author(s):
Key Takeaways
- The buy-and-bill process in dermatology enhances efficiency and financial predictability but is underutilized compared to other fields.
- Topical JAK inhibitors, like ruxolitinib, show effectiveness and potential pediatric applications, with safety studies being crucial.
Dermatology Times is recapping our top expert interviews from the month of February.
Biologic Treatments and Workflow Optimization
Initiating and Navigating the Buy-and-Bill Process
Omar Noor, MD, FAAD, discussed the buy-and-bill process for biologic treatments in dermatology, emphasizing its efficiency and financial predictability. He outlined a streamlined workflow, from treatment selection and insurance coordination to rapid medication delivery and reimbursement. Despite its success in other medical fields, buy-and-bill remains underutilized in dermatology. Noor highlighted its benefits for patient care and practice management, particularly for biologics like tildrakizumab, and encouraged clinicians to adopt and customize the model.
What’s Next for Topical JAK Inhibitors?
Matthew Zirwas, MD, discussed advancements in topical Janus kinase (JAK) inhibitors, particularly ruxolitinib (Opzelura). Zirwas highlighted the effectiveness of ruxolitinib compared to traditional topical steroids, its long-term efficacy, and its potential pediatric applications. He emphasized the importance of safety studies, especially in children. Zirwas also previewed delgocitinib, a topical JAK inhibitor for hand eczema, and discussed how it differs in assessment from atopic dermatitis.
MORE INSIGHTS FROM ZIRWAS: Matthew Zirwas, MD, Previews South Beach Symposium
Rezpeg vs Existing Therapies: A Paradigm Shift in Atopic Dermatitis Treatment
Jonathan Zalevsky, PhD, chief of R&D at Nektar, discussed Rezpeg’s unique mechanism of action, which differs from current biologics like dupilumab and tralokinumab. Unlike these drugs, which target inflammatory cytokines IL-4 and IL-13, Rezpeg stimulates regulatory T cells (Tregs) to suppress inflammation. Zalevsky explained that this Treg activation can help restore immune balance and reduce atopic dermatitis-related inflammation.
MORE INSIGHTS FROM ZALEVSKY: Tackling Unmet Needs in Dermatology With Rezpegaldesleukin; Nektar's Jonathan Zalevsky, PhD, Dives Into Rezpegaldesleukin Fast Track Designation for Atopic Dermatitis
Pediatric Dermatology
What’s New in the Medicine Chest: Vitiligo
James Del Rosso, DO, highlighted emerging therapies and real-world applications for refractory pediatric vitiligo at Winter Clinical Miami 2025. He discussed the efficacy of topical ruxolitinib, emphasizing the need for patience in treatment. Off-label options, such as topical roflumilast and oral upadacitinib, have shown promise in difficult-to-treat cases. Case studies demonstrated successful outcomes, including rapid repigmentation with ruxolitinib. Del Rosso stressed the importance of balancing clinical trial data with real-world evidence to optimize treatment strategies for pediatric vitiligo.
MORE INSIGHTS FROM DEL ROSSO: What’s New in the Medicine Chest: Psoriasis
Balancing Adolescent Acne Treatment and Well-being
Nanette Silverberg, MD, spoke about acne's psychological impact on adolescents. She noted high rates of depression, anxiety, and suicidality in acne patients, worsened by the COVID-19 pandemic. Silverberg stressed that untreated acne poses a greater psychological risk than treatments like isotretinoin. She advocates for interdisciplinary care involving dermatologists, psychiatrists, and therapists, and emphasizes emotional resilience through social support and goal-setting. Silverberg also discussed advances in acne treatments, highlighting retinoids, benzoyl peroxide concerns, and the importance of individualized care for diverse populations.
MORE INSIGHTS FROM SILVERBERG: The Future of Pediatric Care at MOPD; Breaking Barriers in Pediatric Vitiligo Treatment; Diagnosing Skin Conditions in Diverse Pediatric Patients
Glynis Ablon, MD, on Getting Involved in Clinical Trials
At the 2025 South Beach Symposium, Glynis Ablon, MD, gave a presentation on clinical trials, discussing key aspects such as budgeting, patient recruitment, and result analysis. She emphasized that clinical trials provide access to novel treatments for difficult cases and offer clinicians a chance to stay at the forefront of new therapies. Despite some challenges, Ablon sees clinical trials as an exciting and educational extension of dermatology practice.
MORE INSIGHTS FROM ABLON: Glynis Ablon, MD, on Getting Involved in Clinical Trials; Nutraceuticals: A Boost for Skin Health
Research and Innovation
Beyond Topicals: Surgical Solutions for Vitiligo
At the 2025 South Beach Symposium, Nada Elbuluk, MD, discussed procedural treatments for refractory vitiligo, emphasizing their role when medical therapies like immunosuppressive agents and phototherapy fail. Elbuluk highlighted melanocyte-keratinocyte transplantation as the most advanced procedural option, noting new technologies that make the procedure more efficient. She stressed the importance of disease stability before considering surgical interventions and expressed hope for expanded insurance coverage to increase accessibility to these treatments for patients with stable, treatment-resistant vitiligo.
Chilukuri’s Approach to Safer Aesthetic Treatments
Suneel Chilukuri, MD, FAAD, FACMS, discussed preventing complications in minimally invasive dermatological procedures, particularly those involving energy-based devices and injectables. He emphasized recognizing patients' predisposition to hyperpigmentation and using pre-treatment protocols like oral tranexamic acid and retinols. For injectable treatments, Chilukuri stressed the importance of technique, warning about the risks of vascular occlusion, often mistaken for infection. He advocates for thorough monitoring and early intervention, using tools like patient photos to track complications. His holistic approach includes strategies for improving blood flow, wound healing, and preventing pigmentation issues.
MORE INSIGHTS FROM CHILUKURI: Four Key Factors When Buying Dermatology Devices
Jacqueline Watchmaker MD, FAAD, Discusses the Innovative InterFuse Treatment Cream for Aging Skin
Jacqueline Watchmaker, MD, FAAD, discussed the benefits of skinbetter science’s new InterFuse Treatment Cream FACE & NECK for aging skin. The cream targets collagen and elastin support to reduce wrinkles and enhance skin firmness. Its updated formulation includes peptide blends for collagen and elastin support, a neuro-calming peptide, and ingredients like squalane and olive tree polyphenols. Clinical trial data from a 12-week study showed significant improvements in skin smoothness, firmness, and crepiness, with over 90% patient satisfaction. Watchmaker emphasized the product’s safety, efficacy, and strong clinical backing.
Naiem Issa, MD, PhD, FAAD, Discusses Holistic Hair Loss Treatments at SBS 2025
Naiem Issa, MD, PhD, FAAD, discussed a holistic approach to treating hair loss. Issa emphasized combining medical and interventional therapies, such as platelet-rich plasma (PRP) therapy, stem cell therapy, and hair transplants. He highlighted PRP’s effectiveness, though noted variations in preparation methods. Issa also addressed scarring alopecia, focusing on reducing inflammation and promoting hair regeneration. Emerging treatments like laser therapy and mesenchymal stem cells offer new hope for patients. Issa stressed the importance of a patient-centered, evidence-based approach in advancing hair loss treatment.
MORE INSIGHTS FROM ISSA: Efficient Screening for Psoriatic Arthritis
Balancing Steroid and Non-Steroid Treatments
Peter Lio, MD, discussed the balance between topical steroids and emerging non-steroidal alternatives. Lio acknowledged that while steroids are often misunderstood as harmful, they remain a vital part of dermatologic care when used responsibly. He recommended using steroids for initial flare-ups and then switching to non-steroidal treatments for maintenance, minimizing potential side effects. Lio also highlighted the growing range of non-steroidal options like JAK inhibitors, PDE4 inhibitors, and aryl hydrocarbon receptor modulators, which offer effective alternatives for long-term management.
MORE INSIGHTS FROM LIO: Beyond the Surface: How Skin Conditions Affect Daily Life
Updates in Clinical Study of Patients of Color
Mona Shahriari, MD, FAAD, addressed several important issues in dermatology, focusing on building patient trust, improving diversity in clinical trials, and enhancing clinical imagery for diverse skin types. Shahriari highlighted the challenges of trust between clinicians and patients, especially in historically underserved communities. She stressed the need for offering clinical trial participation as an option to foster trust. Shahriari also discussed the underrepresentation of diverse populations in trials, which limits understanding of drug efficacy across ethnicities.
Patrick Burnett, MD, PhD, Highlights Arcutis’ New Seborrheic Dermatitis Initiative With Odell Beckham Jr.
Patrick Burnett, MD, PhD, of Arcutis Biotherapeutics, discussed the partnership with Odell Beckham Jr. to raise awareness of seborrheic dermatitis and roflumilast foam (Zoryve) 0.3%. Beckham, who struggled with the condition, praised the foam’s effectiveness. Burnett highlighted the challenges of diagnosing seborrheic dermatitis, especially in patients with skin of color, and noted that roflumilast foam, approved in 2023, offers a much-needed new treatment option for patients.
Skin Cancer and Technology in Dermatology
How PathAI’s PathAssist Derm Tool Aims to Enhance Skin Cancer Diagnosis and Workflow Efficiency
Andy Beck, MD, PhD, CEO of PathAI, discussed the development of PathAssist Derm, a tool to assist dermatopathologists in diagnosing skin malignancies. Designed to predict diagnoses for 17 skin conditions, including actinic keratoses and melanomas, the tool was validated for accuracy across various skin diseases. Built using a machine-learning model trained on millions of images and dermatopathology slides, PathAssist Derm aims to enhance diagnostic precision and efficiency. Currently for research use, the tool is being piloted for clinical integration with plans for FDA clearance and further validation.
MORE INSIGHTS FROM BECK: The Future of AI in Dermatology with Andy Beck, MD, PhD
Advancements in Acne and Rosacea Treatments
Advancing Acne Care: New Therapies and Technologies
Christopher Bunick, MD, PhD, discussed advancements in acne and rosacea treatments. He highlighted sarecycline, a gut-friendly antibiotic for acne, and sub-microbial dosing of minocycline and doxycycline for rosacea. Bunick also noted the efficacy of advanced lasers targeting sebaceous glands for acne, offering an alternative to oral isotretinoin. He stressed the importance of early treatment to prevent scarring and pigmentation issues, advocating for personalized, evidence-based approaches for better patient outcomes.
MORE INSIGHTS FROM BUNICK: South Beach Symposium 2025: A Comprehensive Dermatology Event; Bunick Highlights Efficacy and Safety of JAK Inhibitors; Topical Corticosteroids: Potency, Vehicles, and Best Practices
Exploring Acne Interventions and the Future of Exosomes in Dermatology
Michael Gold, MD, highlighted exosomes as vital in regenerative medicine, aiding cell communication. However, he stressed that exosomes should not be injected in the US due to FDA regulations, recommending topical applications with microneedling or lasers. Gold also discussed advances in acne treatment, emphasizing a combined approach of medical therapies and devices targeting C. acnes bacteria and sebaceous glands. He urged practitioners to adopt evidence-based treatments, scrutinizing clinical data before incorporating new technologies.
MORE INSIGHTS FROM GOLD: Michael Gold, MD, on the Energy, Excitement, and Innovation of South Beach Symposium; Tackling Skin Laxity and Pigmentation: Technologies in Focus at SBS 2025
Enhancements in Psoriasis and Psoriatic Arthritis Treatment
Jeff Stark, MD: Enhancing Flexibility and Personalized Treatment with 320 mg Bimekizumab Dosage
Jeff Stark, MD, discussed the recent approval of a 320 mg dosage of bimekizumab (Bimzelx) at UCB. The new pre-filled syringe and autoinjector options provide more flexibility for patients. Approved in October 2024, the 320 mg dose was shown to have similar drug exposure and safety to the 160 mg version, though efficacy wasn't directly studied. Stark emphasized the convenience and tailored treatment options for patients with plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa. Looking forward, UCB plans further research, including pediatric trials and exploring bimekizumab’s potential in other inflammatory diseases.
Dermatology Practice Management
Tips and Tricks for Successful Practice Management with Leon Kircik, MD
At the 2025 South Beach Symposium, Leon Kircik, MD, discussed optimizing patient care and managing a successful dermatology practice. He emphasized the importance of time management, delegating tasks to well-trained medical assistants, and using body language to improve patient interactions. Kircik also expressed concerns about the growing reliance on technology in practice management and advised against spreading oneself too thin across multiple locations. He highlighted the benefits of integrating clinical trials into practice, with a focus on targeting the right trials for the patient base.
MORE INSIGHTS FROM KIRCIK: PsA Management: Psoriasis Beyond Skin Symptoms
Optimizing Rural Dermatology: Lisa Swanson, MD, FAAD, on Effective Care Strategies
Lisa Swanson, MD, FAAD, shared strategies for treating rural dermatology patients. She emphasized the importance of effective initial treatments, as follow-ups are often impractical due to travel constraints. Swanson discussed approaches for common conditions, including using topical medication for warts, fungal cultures for ringworm, and ixekizumab (Taltz) for guttate psoriasis. She also highlighted the value of telehealth for follow-ups, though she noted challenges with declining insurance coverage post-pandemic. Swanson encouraged clinicians to advocate for continued telehealth coverage to improve patient outcomes in rural areas.
Aesthetic Dermatology and Empowerment
Aesthetic Treatments: More Than Just Enhancements, A Path to Empowerment
Merz Aesthetics' recent global study reveals the psychological and emotional benefits of aesthetic treatments, beyond just enhancing appearance. Terri Phillips, MD, FAAP, chief medical affairs officer for Merz Aesthetics, explained that the study, surveying 15,000 consumers across 15 countries, found that aesthetic procedures boost self-confidence and social well-being. 72% of respondents felt confident in who they are, and 74% believed self-confidence impacts social well-being. Aesthetic treatments also help individuals align their external appearance with their internal self-perception. Generational differences showed older adults seek treatments for age management, while younger generations are influenced by social media and beauty standards.
How the LIMITLESS Initiative Supports Female Leaders in Dermatology
Melinda (Mindy) Haws, MD, immediate past president of The Aesthetic Society, discussed the LIMITLESS program, an initiative designed to support women's leadership in dermatology and plastic surgery. Launched by Allergan Aesthetics in partnership with the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society, LIMITLESS amplifies the voices of female leaders and provides guidance for women aspiring to leadership roles. While dermatology has made strides with women comprising 52-61% of practicing dermatologists, plastic surgery has a significant gender gap, with only 20% of board-certified surgeons being women.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
Related Videos
Related Content
